Form 4: 1315 Capital II, reports acquisition/exercise transactions in IDXG

Rhea-AI Filing Summary

1315 Capital II, L.P. reported acquisition or exercise transactions in a Form 4 filing for IDXG. The filing lists transactions totaling 9,424,941 shares at a weighted average price of $2.02 per share. Following the reported transactions, holdings were 9,405,941 shares.

Insights

Equity structure and insider-transactions analyst

Large preferred-to-common conversion increases reported common holdings without new cash.

1315 Capital II, L.P., a 10% owner of Interpace Biosciences, converted 19,000 shares of Series C Convertible Preferred Stock into 9,405,941 common shares at a $2.02 conversion price. This shifts its position from preferred to common equity via a non-cash derivative conversion.

The filing shows 9,405,941 common shares held directly after the transaction and no remaining Series C Preferred Stock for this holder. The partnership’s general partner entities may be deemed to share voting and investment power, but they expressly disclaim beneficial ownership beyond any pecuniary interest.

Because this is a conversion rather than an open-market trade, it primarily affects the holder’s security mix rather than signaling a clear buy or sell decision. Future company filings may provide additional context on overall share count and how this conversion fits into the broader capital structure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

1315 Capital II, L.P.

(Last) (First) (Middle)

C/O INTERPACE BIOSCIENCES, INC.

WATERVIEW PLAZA, SUITE 310 2001 ROUTE 46

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTERPACE BIOSCIENCES, INC. [ IDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026(1)		C		9,405,941	A	$2.02(2)	9,405,941	D(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	$2.02(2)	01/20/2026(1)		C			19,000	10/11/2024	(5)	Common Stock	9,405,941	$0	0	D(3)(4)

Explanation of Responses:

1. On January 20, 2026, 19,000 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.01 per share (the "Series C Preferred Shares"), were converted into 9,405,941 shares of the Issuer's common stock, par value $0.01 per share (the "Common Stock").

2. The Series C Preferred Shares were convertible into a number of shares of Common Stock equal to the initial stated value per Series C Share of $1,000 divided by the initial conversion price of $2.02 per shares and then multiplied by the number of Series C Preferred Shares to be converted.

3. These securities are held of record by 1315 Capital II, L.P. (the "Investor"). 1315 Capital GP II, L.P. ("1315 Capital GP") is the general partner of the Investor and 1315 Capital Ultimate Holdings, LLC ("1315 Capital Ultimate") is the general partner of 1315 Capital GP. By virtue of such relationship, each of 1315 Capital GP and 1315 Capital Ultimate may be deemed to have voting and investment power with respect to the securities held by the Investor noted above and as a result may be deemed to have beneficial ownership over such securities.

4. Each of 1315 Capital GP and 1315 Capital Ultimate disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

5. The Series C Convertible Preferred Stock had no expiration date.

	1315 Capital II, L.P. By: 1315 Capital GP II, L.P., its general partner; By: 1315 Capital Ultimate Holdings, LLC, its general partner; By: Adele C. Oliva, Sole Member /s/ Adele C. Oliva	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 1315 Capital II, L.P. report for Interpace Biosciences (IDXG)?

1315 Capital II, L.P. reported converting Series C Convertible Preferred Stock into common shares of Interpace Biosciences. On January 20, 2026, it converted 19,000 preferred shares into 9,405,941 shares of common stock through a derivative conversion, rather than an open-market purchase.

How many Interpace Biosciences (IDXG) common shares were received in the reported Form 4 conversion?

The insider received 9,405,941 shares of Interpace Biosciences common stock. These shares came from converting 19,000 Series C Convertible Preferred Shares, using an initial conversion price of $2.02 per share as described in the transaction’s explanatory footnotes.

What was converted in the Interpace Biosciences (IDXG) Form 4 filed by 1315 Capital II, L.P.?

The filing shows a conversion of 19,000 shares of Series C Convertible Preferred Stock into common stock. After this derivative conversion, 1315 Capital II, L.P. held 9,405,941 common shares and no remaining Series C Preferred Stock for this reported position.

Was the Interpace Biosciences (IDXG) insider transaction a buy or a sale of common stock?

The transaction was a derivative conversion, not an open-market buy or sale. Series C Convertible Preferred Stock was exchanged into common shares at a $2.02 conversion price, changing the type of security held without reporting a traditional market purchase or sale.

Who is the reporting person in the Interpace Biosciences (IDXG) Form 4 and what is their role?

The reporting person is 1315 Capital II, L.P., identified as a 10% owner of Interpace Biosciences. Related general partner entities may be deemed to share voting and investment power, but they disclaim beneficial ownership beyond any pecuniary interest, according to the filing footnotes.